Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: A controlled randomized crossover study

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 9, 2011, Pages 1816-1824

  Van Zaane, B ^a,b   Squizzato, A ^b,c   Debeij, J ^d   Dekkers, O M ^d   Meijers, J C M ^b   Van Zanten, A P ^a   Buller H R ^b   Gerdes, V E A ^a,b   Cannegieter, S C ^d   Brandjes, D P M ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Coagulation; Fibrinolysis; Hemostasis; Hyperthyroidism; Thyroid hormone

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; LEVOTHYROXINE; LIOTHYRONINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THYROID HORMONE; THYROTROPIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EXPOSURE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEART PALPITATION; HEART RATE; HORMONE DETERMINATION; HUMAN; INCREASED APPETITE; INHIBITION KINETICS; INSOMNIA; LIOTHYRONINE BLOOD LEVEL; MALE; MORNING DOSAGE; MUSCLE WEAKNESS; NERVOUSNESS; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SWEATING; SYSTOLIC BLOOD PRESSURE; THYROTROPIN BLOOD LEVEL;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; CROSS-OVER STUDIES; FEMALE; FIBRINOLYSIS; HUMANS; HYPERTHYROIDISM; MALE; RISK FACTORS; THYROID HORMONES; THYROXINE; VENOUS THROMBOSIS;

EID: 80052419747     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04430.x     Document Type: Article

References (39)

1. Doyle JB. Obstruction of the longitudinal sinus. Arch Neurol Psychiatry 1927; 29: 374-82.
2. Lodha A, Haran M, Frankel R, Shani J. Thyrotoxicosis causing arterial and venous thrombosis. Am J Med Sci 2009; 338: 428.
3. Mouton S, Nighoghossian N, Berruyer M, Derex L, Philippeau F, Cakmak S, Honnorat J, Hermier M, Trouillas P. Hyperthyroidism and cerebral venous thrombosis. Eur Neurol 2005; 54: 78-80.
4. Siegert CE, Smelt AH, de Bruin TW. Superior sagittal sinus thrombosis and thyrotoxicosis. Possible association in two cases. Stroke 1995; 26: 496-7.
5. Squizzato A, Vitale J, Gerdes VE, Romualdi E, Buller HR, Ageno W. Recurrent deep venous thrombosis during optimal anticoagulation and overt hyperthyroidism: a case report. Blood Coagul Fibrinolysis 2007; 18: 801-3.
6. Verberne HJ, Fliers E, Prummel MF, Stam J, Brandjes DP, Wiersinga WM. Thyrotoxicosis as a predisposing factor for cerebral venous thrombosis. Thyroid 2000; 10: 607-10.
7. Danescu L, Badshah A, Danescu S, Janjua M, Marandici A, Matta F, Yaekoub A, Malloy D, Stein PD. Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost 2009; 15: 676-80.
8. Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost 2009; 35: 288-94.
9. Squizzato A, Romualdi E, Piantanida E, Gerdes VE, Buller HR, Tanda M, Bartalena L, Venco A, Ageno W. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost 2007; 97: 803-6.
10. Cannegieter SC, Debeij J, Dekkers OM, Christiansen SC, Naess I, Asvold BO, Hammerstrom J, Rosendaal FR. Increased levels of thyroxin increase the risk of venous thrombosis. J Thromb Haemost 2009; 7: Abstract OC-WE-013.
11. van Zaane B, Squizzato A, Huijgen R, van Zanten AP, Fliers E, Cannegieter SC, Buller HR, Gerdes VE, Brandjes DP. Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood 2010; 115: 4344-9.
12. Erem C. Thyroid disorders and hypercoagulability. Semin Thromb Hemost 2011; 37: 17-26.
13. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab 2007; 92: 2415-20.
14. Debeij J, Cannegieter SC, van ZB, Smit JW, Corssmit EP, Rosendaal FR, Romijn JA, Dekkers OM. The effect of changes in thyroxine and thyroid-stimulating hormone levels on the coagulation system. J Thromb Haemost 2010; 8: 2823-6.
15. Demir T, Akinci B, Comlekci A, Karaoglu O, Ozcan MA, Yener S, Yuksel F, Secil M, Yesil S. Levothyroxine (LT4) suppression treatment for benign thyroid nodules alters coagulation. Clin Endocrinol (Oxf) 2009; 71: 446-50.
16. Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab 2007; 92: 3006-12.
17. Stuijver DJ, van Zaane B, Squizzato A, Meijers JC, Otten HM. The effects of an extremely high dose of levothyroxine on coagulation and fibrinolysis. J Thromb Haemost 2010; 8: 1427-8.
18. Graninger W, Pirich KR, Speiser W, Deutsch E, Waldhausl WK. Effect of thyroid hormones on plasma protein concentrations in man. J Clin Endocrinol Metab 1986; 63: 407-11.
19. Rogers JS, Shane SR. Factor VIII activity in normal volunteers receiving oral thyroid hormone. J Lab Clin Med 1983; 102: 444-9.
20. Burggraaf J, Lalezari S, Emeis JJ, Vischer UM, de Meyer PH, Pijl H, Cohen AF. Endothelial function in patients with hyperthyroidism before and after treatment with propranolol and thiamazol. Thyroid 2001; 11: 153-60.
21. Horne MK3rd, Singh KK, Rosenfeld KG, Wesley R, Skarulis MC, Merryman PK, Cullinane A, Costello R, Patterson A, Eggerman T, Bernstein DM, Pucino F, Csako G. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab 2004; 89: 4469-73.
22. Marongiu F, Conti M, Murtas ML, Mameli G, Sorano GG, Martino E. Activation of blood coagulation and fibrinolysis in Graves' disease. Horm Metab Res 1991; 23: 609-11.
23. Hemker HC, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoord R, Lecompte T, Beguin S. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: 249-53.
24. Beltran-Miranda CP, Khan A, Jaloma-Cruz AR, Laffan MA. Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia 2005; 11: 326-34.
25. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6: 125-31.
26. Stuyver DJ, van Zaane B, Squizzato A, Meijers JC, Otten HM. The effects of an extremely high dose of levothyroxine on coagulation and fibrinolysis. J Thromb Haemost 2010; 8: 1427-8.
27. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-5.
28. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008; 5: e97.
29. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
30. Franchini M, Lippi G, Manzato F, Vescovi PP. Thyroid-associated autoimmune coagulation disorders. J Thromb Thrombolysis 2010; 29: 87-91.
31. Hoylaerts MF, Thys C, Arnout J, Vermylen J. Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Blood 1998; 91: 2810-7.
32. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-9.
33. Liu L, Wang X, Lin Z, Wu H. Elevated plasma levels of VWF:Ag in hyperthyroidism are mediated through beta-adrenergic receptors. Endocr Res 1993; 19: 123-33.
34. Takamura N, Akilzhanova A, Hayashida N, Kadota K, Yamasaki H, Usa T, Nakazato M, Maeda T, Ozono Y, Aoyagi K. Thyroid function is associated with carotid intima-media thickness in euthyroid subjects. Atherosclerosis 2009; 204: e77-81.
35. Vischer UM, Wollheim CB. Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Haemost 1997; 77: 1182-8.
36. Baumgartner-Parzer SM, Wagner L, Reining G, Sexl V, Nowotny P, Muller M, Brunner M, Waldhausl W. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J Endocrinol 1997; 154: 231-9.
37. Niessen RW, Pfaffendorf BA, Sturk A, Lamping RJ, Schaap MC, Hack CE, Peters M. The influence of insulin, beta-estradiol, dexamethasone and thyroid hormone on the secretion of coagulant and anticoagulant proteins by HepG2 cells. Thromb Haemost 1995; 74: 686-92.
38. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS, Lin KH. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology 2004; 145: 2804-14.
39. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, Klein I, Baxter JD, Angelin B. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362: 906-16.